APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

Selected research

Industry Growth & Trends

Global Biologics and Biosimilars Industry Growth and Trends Forecast to 2032

25 December 2025110 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

Read the full market overview

Report Scope

This report provides a structured, data-driven view of the global Biologics and Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biologics and Biosimilars market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biologics and Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biologics and Biosimilars.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biologics and Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biologics and Biosimilars Market by Company

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Monoclonal Antibodies Table 2. Major Company of Interferon Table 3. Major Company of Erythropoietin Table 4. Major Company of Insulin Table 5. Major Company of Vaccines Table 6. Major Company of Others Table 7. Global Biologics and Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 9. Global Biologics and Biosimilars Sales Market Share in Volume by Type (2021-2026) Table 10. Global Biologics and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 11. Global Biologics and Biosimilars Sales Market Share in Value by Type (2021-2026) Table 12. Global Biologics and Biosimilars Price by Type (2021-2026) & (USD/Unit) Table 13. Global Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 14. Global Biologics and Biosimilars Sales Market Share in Volume by Type (2027-2032) Table 15. Global Biologics and Biosimilars Sales by Type (2027-2032) & (US$ Million) Table 16. Global Biologics and Biosimilars Sales Market Share in Value by Type (2027-2032) Table 17. Global Biologics and Biosimilars Price by Type (2027-2032) & (USD/Unit) Table 18. North America Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 19. North America Biologics and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 21. Europe Biologics and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Biologics and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 25. Latin America Biologics and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Biologics and Biosimilars Sales by Type (2021-2026) & (US$ Million) Table 28. Biologics and Biosimilars Industry Trends Table 29. Biologics and Biosimilars Industry Drivers Table 30. Biologics and Biosimilars Industry Opportunities and Challenges Table 31. Biologics and Biosimilars Industry Restraints Table 32. Global Biologics and Biosimilars Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Biologics and Biosimilars Revenue Market Share by Company (2021-2026) Table 34. Global Biologics and Biosimilars Sales by Company (2021-2026) & (K Units) Table 35. Global Biologics and Biosimilars Sales Share by Company (2021-2026) Table 36. Global Biologics and Biosimilars Market Price by Company (2021-2026) & (USD/Unit) Table 37. Global Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Biologics and Biosimilars Major Company Production Sites and Headquarters Table 39. Global Biologics and Biosimilars Company, Product Type & Application Table 40. Global Biologics and Biosimilars Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Biologics and Biosimilars Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Biologics and Biosimilars Sales by Region (2021-2026) & (K Units) Table 45. Global Biologics and Biosimilars Sales Market Share in Volume by Region (2021-2026) Table 46. Global Biologics and Biosimilars Sales by Region (2021-2026) & (US$ Million) Table 47. Global Biologics and Biosimilars Sales Market Share in Value by Region (2021-2026) Table 48. Global Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 49. Global Biologics and Biosimilars Sales by Region (2027-2032) & (K Units) Table 50. Global Biologics and Biosimilars Sales Market Share in Volume by Region (2027-2032) Table 51. Global Biologics and Biosimilars Sales by Region (2027-2032) & (US$ Million) Table 52. Global Biologics and Biosimilars Sales Market Share in Value by Region (2027-2032) Table 53. Global Biologics and Biosimilars Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 54. Global Biologics and Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 56. Global Biologics and Biosimilars Sales Market Share in Volume by Application (2021-2026) Table 57. Global Biologics and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 58. Global Biologics and Biosimilars Sales Market Share in Value by Application (2021-2026) Table 59. Global Biologics and Biosimilars Price by Application (2021-2026) & (USD/Unit) Table 60. Global Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 61. Global Biologics and Biosimilars Sales Market Share in Volume by Application (2027-2032) Table 62. Global Biologics and Biosimilars Sales by Application (2027-2032) & (US$ Million) Table 63. Global Biologics and Biosimilars Sales Market Share in Value by Application (2027-2032) Table 64. Global Biologics and Biosimilars Price by Application (2027-2032) & (USD/Unit) Table 65. North America Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 66. North America Biologics and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 68. Europe Biologics and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Biologics and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 72. Latin America Biologics and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Biologics and Biosimilars Sales by Application (2021-2026) & (US$ Million) Table 75. Roche Company Information Table 76. Roche Business Overview Table 77. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 78. Roche Biologics and Biosimilars Product Portfolio Table 79. Roche Recent Development Table 80. Amgen Company Information Table 81. Amgen Business Overview Table 82. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 83. Amgen Biologics and Biosimilars Product Portfolio Table 84. Amgen Recent Development Table 85. AbbVie Company Information Table 86. AbbVie Business Overview Table 87. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. AbbVie Biologics and Biosimilars Product Portfolio Table 89. AbbVie Recent Development Table 90. Sanofi-Aventis Company Information Table 91. Sanofi-Aventis Business Overview Table 92. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Sanofi-Aventis Biologics and Biosimilars Product Portfolio Table 94. Sanofi-Aventis Recent Development Table 95. Johnson & Johnson Company Information Table 96. Johnson & Johnson Business Overview Table 97. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 99. Johnson & Johnson Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Pfizer Biologics and Biosimilars Product Portfolio Table 104. Pfizer Recent Development Table 105. Novo Nordisk Company Information Table 106. Novo Nordisk Business Overview Table 107. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 109. Novo Nordisk Recent Development Table 110. Eli Lilly Company Information Table 111. Eli Lilly Business Overview Table 112. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. Eli Lilly Biologics and Biosimilars Product Portfolio Table 114. Eli Lilly Recent Development Table 115. Novartis Company Information Table 116. Novartis Business Overview Table 117. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. Novartis Biologics and Biosimilars Product Portfolio Table 119. Novartis Recent Development Table 120. Merck Company Information Table 121. Merck Business Overview Table 122. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 123. Merck Biologics and Biosimilars Product Portfolio Table 124. Merck Recent Development Table 125. 3sbio Company Information Table 126. 3sbio Business Overview Table 127. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 128. 3sbio Biologics and Biosimilars Product Portfolio Table 129. 3sbio Recent Development Table 130. Changchun High Tech Company Information Table 131. Changchun High Tech Business Overview Table 132. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 133. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 134. Changchun High Tech Recent Development Table 135. CP Guojian Company Information Table 136. CP Guojian Business Overview Table 137. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 138. CP Guojian Biologics and Biosimilars Product Portfolio Table 139. CP Guojian Recent Development Table 140. Biotech Company Information Table 141. Biotech Business Overview Table 142. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 143. Biotech Biologics and Biosimilars Product Portfolio Table 144. Biotech Recent Development Table 145. Gelgen Company Information Table 146. Gelgen Business Overview Table 147. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 148. Gelgen Biologics and Biosimilars Product Portfolio Table 149. Gelgen Recent Development Table 150. Innovent Company Information Table 151. Innovent Business Overview Table 152. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 153. Innovent Biologics and Biosimilars Product Portfolio Table 154. Innovent Recent Development Table 155. Dong Bao Company Information Table 156. Dong Bao Business Overview Table 157. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 158. Dong Bao Biologics and Biosimilars Product Portfolio Table 159. Dong Bao Recent Development Table 160. Ganlee Company Information Table 161. Ganlee Business Overview Table 162. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 163. Ganlee Biologics and Biosimilars Product Portfolio Table 164. Ganlee Recent Development Table 165. United Laboratories Company Information Table 166. United Laboratories Business Overview Table 167. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 168. United Laboratories Biologics and Biosimilars Product Portfolio Table 169. United Laboratories Recent Development Table 170. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 171. North America Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 172. North America Biologics and Biosimilars Sales Market Share by Country (2021-2026) Table 173. North America Biologics and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 174. North America Biologics and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 175. North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. North America Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 177. North America Biologics and Biosimilars Market Share by Country (2021-2026) Table 178. North America Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. North America Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 180. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 181. Europe Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 182. Europe Biologics and Biosimilars Sales Market Share by Country (2021-2026) Table 183. Europe Biologics and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 184. Europe Biologics and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 185. Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Europe Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 187. Europe Biologics and Biosimilars Market Share by Country (2021-2026) Table 188. Europe Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Europe Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 190. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 191. Asia-Pacific Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 192. Asia-Pacific Biologics and Biosimilars Sales Market Share by Country (2021-2026) Table 193. Asia-Pacific Biologics and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 194. Asia-Pacific Biologics and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 195. Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Asia-Pacific Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 197. Asia-Pacific Biologics and Biosimilars Market Share by Country (2021-2026) Table 198. Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Asia-Pacific Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 200. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 201. Latin America Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 202. Latin America Biologics and Biosimilars Sales Market Share by Country (2021-2026) Table 203. Latin America Biologics and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 204. Latin America Biologics and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 205. Latin America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. Latin America Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 207. Latin America Biologics and Biosimilars Market Share by Country (2021-2026) Table 208. Latin America Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. Latin America Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 210. Middle East and Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 211. Middle East and Africa Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 212. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2021-2026) Table 213. Middle East and Africa Biologics and Biosimilars Sales Forecast by Country (2027-2032) & (K Units) Table 214. Middle East and Africa Biologics and Biosimilars Sales Market Share Forecast by Country (2027-2032) Table 215. Middle East and Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 216. Middle East and Africa Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 217. Middle East and Africa Biologics and Biosimilars Market Share by Country (2021-2026) Table 218. Middle East and Africa Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 219. Middle East and Africa Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Biologics and Biosimilars Distributors List Table 223. Biologics and Biosimilars Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Image Figure 2. Global Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics and Biosimilars Sales (2021-2032) & (K Units) Figure 5. Monoclonal Antibodies Image Figure 6. Global Monoclonal Antibodies Sales YoY Growth (2021-2032) & (K Units) Figure 7. Interferon Image Figure 8. Global Interferon Sales YoY Growth (2021-2032) & (K Units) Figure 9. Erythropoietin Image Figure 10. Global Erythropoietin Sales YoY Growth (2021-2032) & (K Units) Figure 11. Insulin Image Figure 12. Global Insulin Sales YoY Growth (2021-2032) & (K Units) Figure 13. Vaccines Image Figure 14. Global Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Biologics and Biosimilars Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Biologics and Biosimilars Market Share by Type 2025 VS 2032 Figure 19. North America Biologics and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 20. North America Biologics and Biosimilars Sales Market Share in Value by Type in 2025 Figure 21. Europe Biologics and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 22. Europe Biologics and Biosimilars Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Biologics and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Biologics and Biosimilars Sales Market Share in Value by Type in 2025 Figure 25. Latin America Biologics and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Biologics and Biosimilars Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Biologics and Biosimilars Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Biologics and Biosimilars Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Tumor Image Figure 32. Global Tumor Sales YoY Growth (2021-2032) & (K Units) Figure 33. Diabetes Image Figure 34. Global Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 35. Cardiovascular Image Figure 36. Global Cardiovascular Sales YoY Growth (2021-2032) & (K Units) Figure 37. Hemophilia Image Figure 38. Global Hemophilia Sales YoY Growth (2021-2032) & (K Units) Figure 39. Others Image Figure 40. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 41. Global Biologics and Biosimilars Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Biologics and Biosimilars Market Share by Application 2025 VS 2032 Figure 43. North America Biologics and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 44. North America Biologics and Biosimilars Sales Market Share in Value by Application in 2025 Figure 45. Europe Biologics and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 46. Europe Biologics and Biosimilars Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific Biologics and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific Biologics and Biosimilars Sales Market Share in Value by Application in 2025 Figure 49. Latin America Biologics and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 50. Latin America Biologics and Biosimilars Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa Biologics and Biosimilars Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa Biologics and Biosimilars Sales Market Share in Value by Application in 2025 Figure 53. North America Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. North America Biologics and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Europe Biologics and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Asia-Pacific Biologics and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Latin America Biologics and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Biologics and Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 70. Middle East and Africa Biologics and Biosimilars Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Biologics and Biosimilars Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. Biologics and Biosimilars Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Others
Applications
  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia
  • Others
Companies covered
  • Roche
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • 3sbio
  • Changchun High Tech
  • CP Guojian
  • Biotech
  • Gelgen
  • Innovent
  • Dong Bao
  • Ganlee
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologics and Biosimilars Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biologics and Biosimilars Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biologics and Biosimilars Market by Type
  6. 1.3.1 Monoclonal Antibodies
  7. 1.3.2 Interferon
  8. 1.3.3 Erythropoietin
  9. 1.3.4 Insulin
  10. 1.3.5 Vaccines
  11. 1.3.6 Others
  12. 1.4 Global Biologics and Biosimilars Market Size by Type
  13. 1.4.1 Global Biologics and Biosimilars Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Biologics and Biosimilars Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Biologics and Biosimilars Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Biologics and Biosimilars Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Biologics and Biosimilars Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Biologics and Biosimilars Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Biologics and Biosimilars Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Biologics and Biosimilars Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biologics and Biosimilars Revenue (2021-2026)
  2. 3.2 Global Top Players by Biologics and Biosimilars Sales (2021-2026)
  3. 3.3 Global Top Players by Biologics and Biosimilars Price (2021-2026)
  4. 3.4 Global Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologics and Biosimilars Major Company Production Sites & Headquarters
  6. 3.6 Global Biologics and Biosimilars Company, Product Type & Application
  7. 3.7 Global Biologics and Biosimilars Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologics and Biosimilars Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
4 Biologics and Biosimilars Regional Status and Outlook
  1. 4.1 Global Biologics and Biosimilars Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biologics and Biosimilars Historic Market Size by Region
  3. 4.2.1 Global Biologics and Biosimilars Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biologics and Biosimilars Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biologics and Biosimilars Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biologics and Biosimilars Forecasted Market Size by Region
  7. 4.3.1 Global Biologics and Biosimilars Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biologics and Biosimilars Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biologics and Biosimilars Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biologics and Biosimilars by Application
  1. 5.1 Biologics and Biosimilars Market by Application
  2. 5.1.1 Tumor
  3. 5.1.2 Diabetes
  4. 5.1.3 Cardiovascular
  5. 5.1.4 Hemophilia
  6. 5.1.5 Others
  7. 5.2 Global Biologics and Biosimilars Market Size by Application
  8. 5.2.1 Global Biologics and Biosimilars Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Biologics and Biosimilars Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Biologics and Biosimilars Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Biologics and Biosimilars Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Biologics and Biosimilars Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Biologics and Biosimilars Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Biologics and Biosimilars Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Biologics and Biosimilars Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Roche
  2. 6.1.1 Roche Company Information
  3. 6.1.2 Roche Business Overview
  4. 6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Roche Biologics and Biosimilars Product Portfolio
  6. 6.1.5 Roche Recent Developments
  7. 6.2 Amgen
  8. 6.2.1 Amgen Company Information
  9. 6.2.2 Amgen Business Overview
  10. 6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amgen Biologics and Biosimilars Product Portfolio
  12. 6.2.5 Amgen Recent Developments
  13. 6.3 AbbVie
  14. 6.3.1 AbbVie Company Information
  15. 6.3.2 AbbVie Business Overview
  16. 6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AbbVie Biologics and Biosimilars Product Portfolio
  18. 6.3.5 AbbVie Recent Developments
  19. 6.4 Sanofi-Aventis
  20. 6.4.1 Sanofi-Aventis Company Information
  21. 6.4.2 Sanofi-Aventis Business Overview
  22. 6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
  24. 6.4.5 Sanofi-Aventis Recent Developments
  25. 6.5 Johnson & Johnson
  26. 6.5.1 Johnson & Johnson Company Information
  27. 6.5.2 Johnson & Johnson Business Overview
  28. 6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  30. 6.5.5 Johnson & Johnson Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Novo Nordisk
  38. 6.7.1 Novo Nordisk Company Information
  39. 6.7.2 Novo Nordisk Business Overview
  40. 6.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  42. 6.7.5 Novo Nordisk Recent Developments
  43. 6.8 Eli Lilly
  44. 6.8.1 Eli Lilly Company Information
  45. 6.8.2 Eli Lilly Business Overview
  46. 6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  48. 6.8.5 Eli Lilly Recent Developments
  49. 6.9 Novartis
  50. 6.9.1 Novartis Company Information
  51. 6.9.2 Novartis Business Overview
  52. 6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novartis Biologics and Biosimilars Product Portfolio
  54. 6.9.5 Novartis Recent Developments
  55. 6.10 Merck
  56. 6.10.1 Merck Company Information
  57. 6.10.2 Merck Business Overview
  58. 6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Merck Biologics and Biosimilars Product Portfolio
  60. 6.10.5 Merck Recent Developments
  61. 6.11 3sbio
  62. 6.11.1 3sbio Company Information
  63. 6.11.2 3sbio Business Overview
  64. 6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 3sbio Biologics and Biosimilars Product Portfolio
  66. 6.11.5 3sbio Recent Developments
  67. 6.12 Changchun High Tech
  68. 6.12.1 Changchun High Tech Company Information
  69. 6.12.2 Changchun High Tech Business Overview
  70. 6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  72. 6.12.5 Changchun High Tech Recent Developments
  73. 6.13 CP Guojian
  74. 6.13.1 CP Guojian Company Information
  75. 6.13.2 CP Guojian Business Overview
  76. 6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
  78. 6.13.5 CP Guojian Recent Developments
  79. 6.14 Biotech
  80. 6.14.1 Biotech Company Information
  81. 6.14.2 Biotech Business Overview
  82. 6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Biotech Biologics and Biosimilars Product Portfolio
  84. 6.14.5 Biotech Recent Developments
  85. 6.15 Gelgen
  86. 6.15.1 Gelgen Company Information
  87. 6.15.2 Gelgen Business Overview
  88. 6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Gelgen Biologics and Biosimilars Product Portfolio
  90. 6.15.5 Gelgen Recent Developments
  91. 6.16 Innovent
  92. 6.16.1 Innovent Company Information
  93. 6.16.2 Innovent Business Overview
  94. 6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Innovent Biologics and Biosimilars Product Portfolio
  96. 6.16.5 Innovent Recent Developments
  97. 6.17 Dong Bao
  98. 6.17.1 Dong Bao Company Information
  99. 6.17.2 Dong Bao Business Overview
  100. 6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
  102. 6.17.5 Dong Bao Recent Developments
  103. 6.18 Ganlee
  104. 6.18.1 Ganlee Company Information
  105. 6.18.2 Ganlee Business Overview
  106. 6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Ganlee Biologics and Biosimilars Product Portfolio
  108. 6.18.5 Ganlee Recent Developments
  109. 6.19 United Laboratories
  110. 6.19.1 United Laboratories Company Information
  111. 6.19.2 United Laboratories Business Overview
  112. 6.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
  114. 6.19.5 United Laboratories Recent Developments
7 North America by Country
  1. 7.1 North America Biologics and Biosimilars Sales by Country
  2. 7.1.1 North America Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biologics and Biosimilars Sales by Country (2021-2026)
  4. 7.1.3 North America Biologics and Biosimilars Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biologics and Biosimilars Market Size by Country
  6. 7.2.1 North America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biologics and Biosimilars Market Size by Country (2021-2026)
  8. 7.2.3 North America Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biologics and Biosimilars Sales by Country
  2. 8.1.1 Europe Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biologics and Biosimilars Sales by Country (2021-2026)
  4. 8.1.3 Europe Biologics and Biosimilars Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biologics and Biosimilars Market Size by Country
  6. 8.2.1 Europe Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biologics and Biosimilars Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biologics and Biosimilars Sales by Country
  2. 9.1.1 Asia-Pacific Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biologics and Biosimilars Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biologics and Biosimilars Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biologics and Biosimilars Market Size by Country
  6. 9.2.1 Asia-Pacific Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biologics and Biosimilars Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biologics and Biosimilars Sales by Country
  2. 10.1.1 South America Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biologics and Biosimilars Sales by Country (2021-2026)
  4. 10.1.3 South America Biologics and Biosimilars Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biologics and Biosimilars Market Size by Country
  6. 10.2.1 South America Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biologics and Biosimilars Market Size by Country (2021-2026)
  8. 10.2.3 South America Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biologics and Biosimilars Sales by Country
  2. 11.1.1 Middle East and Africa Biologics and Biosimilars Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biologics and Biosimilars Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biologics and Biosimilars Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biologics and Biosimilars Market Size by Country
  6. 11.2.1 Middle East and Africa Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biologics and Biosimilars Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biologics and Biosimilars Value Chain Analysis
  2. 12.1.1 Biologics and Biosimilars Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biologics and Biosimilars Production Mode & Process
  7. 12.2 Biologics and Biosimilars Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biologics and Biosimilars Distributors
  10. 12.2.3 Biologics and Biosimilars Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst